Your browser doesn't support javascript.
loading
Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART.
Ehrenberg, Alexander J; Kelberman, Michael A; Liu, Kathy Y; Dahl, Martin J; Weinshenker, David; Falgàs, Neus; Dutt, Shubir; Mather, Mara; Ludwig, Mareike; Betts, Matthew J; Winer, Joseph R; Teipel, Stefan; Weigand, Alexandra J; Eschenko, Oxana; Hämmerer, Dorothea; Leiman, Marina; Counts, Scott E; Shine, James M; Robertson, Ian H; Levey, Allan I; Lancini, Elisa; Son, Gowoon; Schneider, Christoph; Egroo, Maxime Van; Liguori, Claudio; Wang, Qin; Vazey, Elena M; Rodriguez-Porcel, Federico; Haag, Lena; Bondi, Mark W; Vanneste, Sven; Freeze, Whitney M; Yi, Yeo-Jin; Maldinov, Mihovil; Gatchel, Jennifer; Satpati, Abhijit; Babiloni, Claudio; Kremen, William S; Howard, Robert; Jacobs, Heidi I L; Grinberg, Lea T.
Afiliación
  • Ehrenberg AJ; Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
  • Kelberman MA; Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, California, USA.
  • Liu KY; Innovative Genomics Institute, University of California, Berkeley, Berkeley, California, USA.
  • Dahl MJ; Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Weinshenker D; Division of Psychiatry, University College London, London, UK.
  • Falgàs N; Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
  • Dutt S; Center for Lifespan Psychology, Max Planck Institute for Human Development, Berlin, Germany.
  • Mather M; Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Ludwig M; Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Betts MJ; Global Brain Health Institute, University of California, San Francisco, San Francisco, California, USA.
  • Winer JR; Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
  • Teipel S; Department of Psychology, University of Southern California, Los Angeles, California, USA.
  • Weigand AJ; Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
  • Eschenko O; Department of Psychology, University of Southern California, Los Angeles, California, USA.
  • Hämmerer D; Department of Biomedical Engineering, University of Southern California, Los Angeles, California, USA.
  • Leiman M; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University, Magdeburg, Germany.
  • Counts SE; Center for Behavioral Brain Sciences, University of Magdeburg, Magdeburg, Germany.
  • Shine JM; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University, Magdeburg, Germany.
  • Robertson IH; Center for Behavioral Brain Sciences, University of Magdeburg, Magdeburg, Germany.
  • Levey AI; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Magdeburg, Germany.
  • Lancini E; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Son G; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Rostock/Greifswald, Rostock, Germany.
  • Schneider C; Department of Psychosomatic Medicine, University Medicine Rostock, Rostock, Germany.
  • Egroo MV; San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California, USA.
  • Liguori C; Department of Computational Neuroscience, Max Planck Institute for Biological Cybernetics, Tuebingen, Germany.
  • Wang Q; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University, Magdeburg, Germany.
  • Vazey EM; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Magdeburg, Germany.
  • Rodriguez-Porcel F; Department of Psychology, University of Innsbruck, Innsbruck, Austria.
  • Haag L; Institute of Cognitive Neuroscience, University College London, London, UK.
  • Bondi MW; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University, Magdeburg, Germany.
  • Vanneste S; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Magdeburg, Germany.
  • Freeze WM; Department of Translational Neuroscience, Michigan State University, Grand Rapids, Michigan, USA.
  • Yi YJ; Department of Family Medicine, Michigan State University, Grand Rapids, Michigan, USA.
  • Maldinov M; Michigan Alzheimer's Disease Research Center, Ann Arbor, Michigan, USA.
  • Gatchel J; Brain and Mind Center, The University of Sydney, Sydney, Australia.
  • Satpati A; Global Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
  • Babiloni C; Goizueta Alzheimer's Disease Research Center, Emory University, Atlanta, Georgia, USA.
  • Kremen WS; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Howard R; Goizueta Institute, Emory University, Atlanta, Georgia, USA.
  • Jacobs HIL; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University, Magdeburg, Germany.
  • Grinberg LT; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Magdeburg, Germany.
Alzheimers Dement ; 19(5): 2182-2196, 2023 05.
Article en En | MEDLINE | ID: mdl-36642985
ABSTRACT
The neuromodulatory subcortical system (NSS) nuclei are critical hubs for survival, hedonic tone, and homeostasis. Tau-associated NSS degeneration occurs early in Alzheimer's disease (AD) pathogenesis, long before the emergence of pathognomonic memory dysfunction and cortical lesions. Accumulating evidence supports the role of NSS dysfunction and degeneration in the behavioral and neuropsychiatric manifestations featured early in AD. Experimental studies even suggest that AD-associated NSS degeneration drives brain neuroinflammatory status and contributes to disease progression, including the exacerbation of cortical lesions. Given the important pathophysiologic and etiologic roles that involve the NSS in early AD stages, there is an urgent need to expand our understanding of the mechanisms underlying NSS vulnerability and more precisely detail the clinical progression of NSS changes in AD. Here, the NSS Professional Interest Area of the International Society to Advance Alzheimer's Research and Treatment highlights knowledge gaps about NSS within AD and provides recommendations for priorities specific to clinical research, biomarker development, modeling, and intervention. HIGHLIGHTS Neuromodulatory nuclei degenerate in early Alzheimer's disease pathological stages. Alzheimer's pathophysiology is exacerbated by neuromodulatory nuclei degeneration. Neuromodulatory nuclei degeneration drives neuropsychiatric symptoms in dementia. Biomarkers of neuromodulatory integrity would be value-creating for dementia care. Neuromodulatory nuclei present strategic prospects for disease-modifying therapies.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos